RenovoRx (RNXT) Gross Margin (2025 - 2026)

RenovoRx (RNXT) posted Gross Margin of 85.08% for Q1 2026, down 3.58% sequentially from 88.24% in Q4 2025, and up 3280.0% YoY from 2.52% in Q1 2025.

RenovoRx (RNXT) Gross Margin (2025 - 2026) Analysis & Trends

RenovoRx has reported Gross Margin for 2 years, with the latest figure at 85.08% in Q1 2026.

Quarterly Gross Margin rose 3280.0% year-over-year to 85.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78.71% (changed N/A YoY) and the FY2025 annual result came in at 70.88%, down 2912.0% from the prior year.
Gross Margin retreated to 85.08% in Q1 2026 per RNXT's latest filing, from 88.24% in the prior quarter.
Over five years, Gross Margin peaked at 88.24% in Q4 2025 and troughed at 52.28% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	90.43%
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	76.90%
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	84.20%
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	63.27%
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	-
10	RenovoRx	61.25 Mn	61.25 Mn	766,000.00	84.27%

Download Data